Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Adaptimmune Therapeutics stock

Learn how to easily invest in Adaptimmune Therapeutics stock.

Adaptimmune Therapeutics Plc is a biotechnology business based in the US. Adaptimmune Therapeutics shares (ADAP) are listed on the NASDAQ and all prices are listed in US Dollars. Adaptimmune Therapeutics employs 494 staff and has a trailing 12-month revenue of around $11.7 million.

How to buy shares in Adaptimmune Therapeutics

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – ADAP – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

Adaptimmune Therapeutics stock price (NASDAQ: ADAP)

Use our graph to track the performance of ADAP stocks over time.

Adaptimmune Therapeutics shares at a glance

Information last updated 2022-10-02.
Latest market close$1.08
52-week range$1.01 - $5.95
50-day moving average $1.86
200-day moving average $2.19
Wall St. target price$5.83
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-1.09

Buy Adaptimmune Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 6 of 6
Name Product Asset types Stock trade fee Minimum deposit Signup bonus
SoFi Invest
Stocks, ETFs, Cryptocurrency
$10 - $100
when you open an account and place a first crypto trade of $50 - $5,000+
A free way to invest in most equities.
Stocks, ETFs, Cryptocurrency
8%-12% of your deposit
when you sign up and deposit at least $50. T&Cs apply.
Trade stocks in the app or online with $0 commissions. Not available in NY, NV, MN, TN, and HI.
Stocks, Options, ETFs, Cryptocurrency
$200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
Stocks, ETFs, Cryptocurrency
Receive a free stock slice worth between $3–$300
when you sign up for an account and deposit at least $20.
Commission-free trading in stocks and ETFs with a social networking twist.
JPMorgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$125 - $625
when you open and fund an account with $25,000 - $250,000+
Stocks, Options, ETFs, Cryptocurrency
Get a free stock
when you successfully sign up and link your bank account.
Make unlimited commission-free trades, plus earn 3% interest on uninvested cash in your account with Robinhood Gold.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Adaptimmune Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Adaptimmune Therapeutics price performance over time

Historical closes compared with the close of $1.075 from 2022-09-30

1 week (2022-09-27) -3.15%
1 month (2022-09-02) -46.78%
3 months (2022-07-01) -34.85%
6 months (2022-03-31) N/A
1 year (2021-09-30) -79.21%
2 years (2020-10-02) -86.58%
3 years (2019-10-04) 1.22
5 years (2017-10-04) 8.74

Is Adaptimmune Therapeutics stock undervalued or overvalued?

Valuing Adaptimmune Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Adaptimmune Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Adaptimmune Therapeutics's PEG ratio

Adaptimmune Therapeutics's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.11. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Adaptimmune Therapeutics's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Adaptimmune Therapeutics financials

Revenue TTM $11.7 million
Gross profit TTM $-104,941,000
Return on assets TTM -28.72%
Return on equity TTM -83.86%
Profit margin 0%
Book value $0.87
Market capitalisation $175.6 million

TTM: trailing 12 months

Adaptimmune Therapeutics share dividends

We're not expecting Adaptimmune Therapeutics to pay a dividend over the next 12 months.

Adaptimmune Therapeutics share price volatility

Over the last 12 months, Adaptimmune Therapeutics's shares have ranged in value from as little as $1.01 up to $5.95. A popular way to gauge a stock's volatility is its "beta".

ADAP.US volatility(beta: 1.75)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Adaptimmune Therapeutics's is 1.7539. This would suggest that Adaptimmune Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Adaptimmune Therapeutics overview

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4 that is in phase II clinical trials with SPEARHEAD-1 for synovial sarcoma and myxoid round cell liposarcoma indications (MRCLS); in phase II clinical trials with SPEARHEAD-2 for patients with head and neck cancer; and in phase I clinical trials for urothelial, melanoma, head and neck, ovarian, non-small cell lung, esophageal and gastric, synovial sarcoma, and MRCLS cancers. The company is also developing ADP-A2AFP, which is in phase I clinical trials for hepatocellular carcinoma; and ADP-A2M4CD8, which is in phase I clinical trial for SPEAR T-cells focusing on treating patients with lung, gastroesophageal, head and neck, ovarian, and bladder cancers. It has a collaboration and license agreement with GSK; third party collaborations with Noile-Immune Biotech Inc. , Alpine Immune Sciences, Inc. , and National Center for Cancer Immune Therapy in Denmark; strategic alliance agreement with the MD Anderson Cancer Center; and co-development and co-commercialization agreement with Universal Cells, Inc.

Frequently asked questions

What percentage of Adaptimmune Therapeutics is owned by insiders or institutions?
Currently 0.172% of Adaptimmune Therapeutics shares are held by insiders and 70.913% by institutions.
How many people work for Adaptimmune Therapeutics?
Latest data suggests 494 work at Adaptimmune Therapeutics.
When does the fiscal year end for Adaptimmune Therapeutics?
Adaptimmune Therapeutics's fiscal year ends in December.
Where is Adaptimmune Therapeutics based?
Adaptimmune Therapeutics's address is: 60 Jubilee Avenue, Abingdon, United Kingdom, OX14 4RX
What is Adaptimmune Therapeutics's ISIN number?
Adaptimmune Therapeutics's international securities identification number is: US00653A1079
What is Adaptimmune Therapeutics's CUSIP number?
Adaptimmune Therapeutics's Committee on Uniform Securities Identification Procedures number is: 00653A107

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site